Nuvalent, Inc. (NUVL) Tuesday reported positive pivotal data from ARROS-1 Phase 1/2 study of zidesamtinib for the treatment of TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC).
In 117 ROS1 TKI pre-treated patients, overall response rate (ORR) was 44% with durability of 78% at 12 months and 62% at 18 months. In patients treated with one prior ROS1 TKI, ORR was 51% with 93% durability at both 12 and 18 months.
The company plans to initiate a rolling NDA submission in July 2025 with completion targeted for the third quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.